Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07. November 2023 16:01 ET
|
Lyra Therapeutics
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
07. November 2023 07:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
16. Oktober 2023 07:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the...
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
12. September 2023 07:00 ET
|
Lyra Therapeutics
Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks Statistically significant improvements in efficacy were...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
06. September 2023 08:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
29. August 2023 07:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory...
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08. August 2023 16:01 ET
|
Lyra Therapeutics
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in the Coming Weeks, with Data Expected in 1H 2024 -- -- Initial Topline...
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
13. Juli 2023 07:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02. Juni 2023 16:01 ET
|
Lyra Therapeutics
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the...
Lyra Therapeutics to Present at Jefferies Healthcare Conference
02. Juni 2023 07:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of...